Promotional webinar sponsored by
Boehringer Ingelheim and Lilly Alliance
for UK HCPs.
Review of the new NICE NG28 guideline and how we can improve clinical outcomes for adults with type 2 diabetes This promotional webinar was originally broadcast on 24 May 2022
This is a recording of the webinar. Please note that the speaker(s) are not able to answer questions from attendees watching the video on- demand.
This resource has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company prior to the symposium. Editorial support for this symposium has been provided by OmniaMed Communications.
Primary Care Network Early Diagnosis Support
Stay up to date with our Primary Care Newsletter
We are Boehringer Ingelheim.
Family-owned. Purpose-led. Innovation-driven: We work to improve health for people and animals.
Aspiring to make new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.
By working collaboratively, we aim to accelerate the delivery of medical breakthroughs to help transform the lives of patients now, and for generations to come. In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.
We are committed to tackling the challenge of climate change. We serve local and global communities through our social impact programme and wevsupport social entrepreneurs who find healthcare solutions for the most vulnerable.
PC-GB-106589 | May 2022